Table 1 Patients’ characteristics at baseline a
Low dose group | High dose group | p value | |
|---|---|---|---|
800 IU/d | 4,370 IU/d | ||
N = 21 | N = 24 | ||
Age (years) | 44.7 ± 10.7 | 43.1 ± 12.3 | 0.7 b |
43.6 (26.7-63.9) | 43.1 (21.7-63.7) | ||
Gender (Male/Female) | F 13 (62%) | F 19 (79%) | 0.2 c |
M 8 (38%) | M 5 (21%) | ||
Time from MS diagnosis (years) | 9.3 ± 7.4 | 6 ± 5.7 | 0.08 d |
8.1 (0.4-32.9) | 3.4 (0.3-19.1) | ||
IFN-β treatment duration (months) | 61.3 ± 46 | 38.9 ± 32.5 | 0.1 d |
59.1 (3.1-144.1) | 23.4 (1.2-96.7) | ||
EDSS | 3.6 ± 2.2 | 2.9 ± 2.0 | 0.4 d |
4.5 (0–7) | 2.5 (0–7) | ||
Patients with relapses during the year preceding randomization | 6/21 (28.6%) | 8/24 (33.3%) | 0.7 c |
Annualized relapse rate during the year preceding randomization | 0.38 ± 0.26 | 0.28 ± 0.23 | 0.6 e |